Conference call scheduled on August 8, 2018 at 4:30 PM ET
NEW HAVEN, Conn., Aug. 02, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) ( BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, today announced that it will release its financial results for the second quarter ended June 30, 2018 on Wednesday, August 8, 2018. The Company will hold a conference call at 4:30 PM Eastern Time on Wednesday, August 8, 2018 to discuss the financial results and provide a business update.
| CONFERENCE CALL & WEBCAST- | |
| Wednesday, August 8, 2018, 4:30 p.m. Eastern Time | |
| Domestic: | 800-347-6311 |
| International: | 323-794-2094 |
| Conference ID: | 8850726 |
| Webcast: | http://public.viavid.com/index.php?id=130885 |
| Replay – Available through September 8, 2018 | |
| Domestic: | 844-512-2921 |
| International: | 412-317-6671 |
| Conference ID: | 8850726 |
About BioXcel Therapeutics, Inc. (BTI):
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology. BTI’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI’s two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. For more information, please visit www.bioxceltherapeutics.com.
Contact Information:
The Ruth Group for BTI:
Lee Roth / Janhavi Mohite
646-536-7012 / 7026
[email protected] / [email protected]
